Abstract:Osteosarcoma (OS) is a malignant bone tumor that mainly occurs in adolescents. It is accompanied by a high rate of lung metastasis, and high mortality. Recent studies have suggested the important roles of tripartite motif-containing (TRIM) family proteins in regulating various substrates and signaling pathways in different tumors. However, the detailed functional role of TRIM family proteins in the progression of OS is still unknown and requires further investigations. In this study, we found that tripartite motif-containing 22 (TRIM22) was downregulated in OS tissues and was hence associated with better prognosis. In vitro and in vivo functional analysis demonstrated that TRIM22 inhibits proliferation and metastasis of OS cells. Nuclear factor erythroid 2-related factor 2 (NRF2), a redox regulator, was identified as a novel target for TRIM22. TRIM22 interacts with and accelerates the degradation of NRF2 by inducing its ubiquitination dependent on its E3 ligase activity but independent of Kelch-like ECH-associated protein 1 (KEAP1). Further, a series of gain- and loss-of-function experiments showed that knockdown or overexpression of NRF2 reversed the functions of knockdown or overexpression of TRIM22 in OS. Mechanistically, TRIM22 inhibited OS progression through NRF2-mediated intracellular reactive oxygen species (ROS) imbalance. ROS production was significantly promoted and mitochondrial potential was remarkably inhibited when overexpressing TRIM22, thus activating AMPK/mTOR signaling. Moreover, TRIM22 was also found to inhibit Warburg effect in OS cells. Autophagy activation was found in OS cells which were overexpressed TRIM22, thus leading to autophagic cell death. Treatment with N-Acetylcysteine (NAC), a ROS scavenger or the autophagy inhibitor 3-Methyladenine (3-MA) abolished the decreased malignant phenotypes in TRIM22 overexpressing OS cells. In conclusion, our study indicated that TRIM22 inhibits OS progression by promoting proteasomal degradation of NRF2 independent of KEAP1, thereby activating ROS/AMPK/mTOR/Autophagy signaling that leads to autophagic cell death in OS. Therefore, our findings indicated that targeting TRIM22/NRF2 could be a promising therapeutic target for treating OS.

Oncogenic Gene TRIM10 Confers Resistance to Cisplatin in Osteosarcoma Cells and Activates the NF‐κB Signaling Pathway

Trim14 Regulates Cell Proliferation and Invasion in Osteosarcoma Via Promotion of the Akt Signaling Pathway

N6-Methyladenosine Modification of the TRIM7 Positively Regulates Tumorigenesis and Chemoresistance in Osteosarcoma Through Ubiquitination of BRMS1

TRIM47 inhibits cisplatin chemosensitivity and endoplasmic reticulum stress-induced apoptosis of ovarian cancer cells

TRIM25 Regulates Oxaliplatin Resistance in Colorectal Cancer by Promoting EZH2 Stability.

TRIM25 Regulates Oxaliplatin Resistance in Colorectal Cancer by Promoting EZH2 Stability

Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway

Telomerase reverse transcriptase promotes chemoresistance by suppressing cisplatin-dependent apoptosis in osteosarcoma cells

Overexpression of TRIM44 mediates the NF-κB pathway to promote the progression of ovarian cancer

TRIM14 Promotes Chemoresistance in Gliomas by Activating Wnt/β-catenin Signaling Via Stabilizing Dvl2

Overexpression of TRIM14 promotes tongue squamous cell carcinoma aggressiveness by activating the NF-kB signaling pathway.

TRIM26 Inhibited Osteosarcoma Progression Through Destabilizing RACK1 and Thus Inactivation of MEK/ERK Signaling.

TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling

TRIM52 plays an oncogenic role in ovarian cancer associated with NF-kB pathway

PRMT5-TRIM21 Interaction Regulates the Senescence of Osteosarcoma Cells by Targeting the TXNIP/p21 Axis

TNFRSF10D expression as a potential biomarker for cisplatin-induced damage and ovarian tumor relapse prediction

FoxG1/BNIP3 axis promotes mitophagy and blunts cisplatin resistance in osteosarcoma

TRIM31 Promotes Glioma Proliferation and Invasion Through Activating NF-κB Pathway.

TRP14 Promotes Resistance to Cisplatin by Inducing Autophagy in Ovarian Cancer.

TRIM11, a Direct Target of Mir-24-3p, Promotes Cell Proliferation and Inhibits Apoptosis in Colon Cancer

CXCR1 Knockdown Improves the Sensitivity of Osteosarcoma to Cisplatin